
-
Wave Life Sciences NasdaqGM:WVE Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Location: Marina One East Tower, Singapore, 018936, Singapore | Website: https://wavelifesciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
764.1M
Cash
243.1M
Avg Qtr Burn
-45.16M
Short % of Float
19.59%
Insider Ownership
16.35%
Institutional Own.
85.15%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
WVE-N531 Details Duchenne muscular dystrophy | NDA Submission | |
WVE-003 Details Huntington's disease | Phase 2/3 Initiation | |
Phase 2 Data readout | ||
WVE-006 Details Alpha-1 Antitrypsin Deficiency | Phase 1/2 Data readout | |
WVE-120101 (SNP1) Details Huntington's disease | Failed Discontinued | |
WVE-004 Details Amyotrophic lateral sclerosis, Frontotemporal dementia with GRN mutations | Failed Discontinued | |
WVE-120102 (SNP2) Details Huntington's disease | Failed Discontinued |